Get to know our clinical trials
Clinical Trial on the Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy.
THE OBJECTIVE OF THIS CLINICAL TRIAL IS TO DETERMINE THE EXTENT TO WHICH THE INVESTIGATIONAL DRUG, AMX0035, IS SAFE AND EFFECTIVE FOR THE TREATMENT OF PSP, AND TO DETERMINE WHETHER IT CAN SLOW DISEASE PROGRESSION.
Technical Summary
- PHASE 3 STUDY ON SAFETY AND EFFICACY OF AMX0035 IN PROGRESSIVE SUPRANUCLEAR PALSY (ORION)
- Code EudraCT: 2023-505893-14-00
- Protocol number: A35-009
- Promoter: Amylyx Pharmaceuticals, Inc
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.